Oregon Health and Science University
Portland, Oregon, 97239, United States
NCT Number: NCT02398292
The purpose of this study is to determine the feasibility (≥ 50% completion rate) of a 6-week nutrition, movement, and mindfulness program for youth with recent diagnosis of psychosis.
Looking for future studies?
Notify Me15 year–25 year
All sexes
Interventional
Not applicable
Portland, Oregon, 97239, United States
The purpose of this study is to determine the feasibility of a 6-week nutrition, movement, and mindfulness program (M³ Program) for youth with a recent diagnosis of psychosis. Program effects on metabolic and mental health outcomes compared to wait-list control will also be assessed. Participants will be 15-25 years of age, and have a recent diagnosis of psychosis. Twenty participants and their study partners (20 study partners) will be equally divided into two cohorts. Participants will sign up for one of the two series on a rolling enrollment basis until both of the program date frames are filled. Participants that signed up for the second series will serve as a wait-list control; outcomes from the participants in the first series will be compared to this group. M³ will be a combination of didactic and experiential training. The course will meet once-a-week for six weeks. Participants will learn how to prepare healthy snacks and meals, make healthy choices when eating out, and interpret food packaging and labels. They will also learn about different forms of mindfulness exercises and movement, such as yoga, martial arts, and a Japanese style of drumming. Feasibility will be assessed throughout the program.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants and their study partners will learn about food, movement, and mindfulness through hands-on curriculum.
Other names: Meals, Mindfulness and Moving Foward Program
Participants will not participate in M3 program but will have same outcomes measured at same time points (baseline, 6 weeks, 12 weeks).
Time frame: 6 weeks
Time frame: 6 and12 weeks
body mass index
Time frame: 6 and12 weeks
waist circumference measured in cm
Time frame: 6 and12 weeks
total cholesterol, triglycerides, HDL, LDL
Time frame: 6 and12 weeks
A rating scale to measure positive symptoms of schizophrenia. The QSANS-QSAPS assessment is administered by a trained health professional and takes 30 to 45 minutes to complete.
Time frame: 6 and12 weeks
A measurement of 'hardiness', or one's ability to successfully cope with stress. The scale draws on a number of resilient characteristics, including patience, tolerance to negative affect, sense of humor, commitment, recognition of limits to control, engaging the support of others, and adaptability. The CD-RISC contains 25 items and asks subjects to rate how they felt over the past month on a Likert-type scale. Total score range is 0 - 100, with higher scores indicating higher levels of resiliency.
Time frame: 6 and12 weeks
: The SF-12 is a 12-item validated shortened version of the SF-36 and was designed to provide a health related quality of life measure that was quick and easy to administer in large population studies. The SF-12 contains a subset of the 12 items from the SF-36 and information from this subset of questions is used to construct a physical and mental component summary score.
Oregon Health and Science University
Other
Meals, Mindfulness & Moving Forward: A Multi-modal Approach to Addressing Cardiovascular Risk and Building Resilience in Youth Suffering From Psychosis
Acronym: M3
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04602741
Mental Disorders, Psychotic Disorders
Toronto, Ontario, Canada
View Trial DetailsNCT07523256
Inflammation, Mental Disorders
Makassar, South Sulawesi, Indonesia
View Trial DetailsNCT05899348
Mental Disorders, Psychotic Disorders
La Jolla, California, United States
View Trial DetailsNCT06038955
Behavior, Behavioral Symptoms
Frederiksberg, Capital Region of Copenhagen, Denmark
View Trial Details